Researchers used Google DeepMind’s AlphaFold2 and ProteinMPNN to speed development of antibody-based probes that can be used to see key functions and chemical changes inside living cells as they ...

The collaboration will leverage Abalone Bio’s Functional Antibody Selection Technology platform for an undisclosed ...

Boehringer Ingelheim begins phase IIa trial of BI 765423, a novel monoclonal antibody targeting IL-11, in patients with idiopathic pulmonary fibrosis: Ingelheim, Germany Thursday, ...

Considering a switch from IVIg to SCIg for primary immunodeficiency? Explore differences in responsibility, side effects, ...

Medically reviewed by Matthew Wosnitzer, MD Key Takeaways The rate of progression of immunoglobulin A nephropathy (IgAN) can ...

Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart –– Recruitment ongoing for ...

Not intended for US and UK audiencesBI 765423 has been developed to target IL-11, a key driver of fibrosisNew study will investigate potential of ...

Cervical lymphadenopathy presents a shared anatomic challenge for clinicians, yet it serves as the divergent starting point ...

Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s ...

An extension was required to provide time to review additional data requested by the FDA to clarify sparsentan’s clinical benefit.

Explore comprehensive treatments for CIDP, including corticosteroids, plasma exchange, immunoglobulin therapy, and others.

IgA nephropathy is a type of kidney disease that is typically treated with various medicines and lifestyle changes. Learn more about IgA nephropathy treatment here.